Proteomics and cancer diagnosis: the potential of mass spectrometry.

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[2]  H. Kuerer,et al.  Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma , 2002, Cancer.

[3]  P. Thibault,et al.  Identification of differentially expressed proteins in human glioblastoma cell lines and tumors , 2003, Glia.

[4]  A. Lu,et al.  Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. , 2002, The Journal of urology.

[5]  E. Diamandis.  Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.

[6]  Nan Hu,et al.  2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.

[7]  V. Álvarez,et al.  Hypertrophic cardiomyopathy: low frequency of mutations in the beta-myosin heavy chain (MYH7) and cardiac troponin T (TNNT2) genes among Spanish patients. , 2003, Clinical chemistry.

[8]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[9]  Sharon L R Kardia,et al.  Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  C. Paweletz,et al.  New approaches to proteomic analysis of breast cancer , 2001, Proteomics.

[11]  F. Miller,et al.  High sequence coverage of proteins isolated from liquid separations of breast cancer cells using capillary electrophoresis-time-of-flight MS and MALDI-TOF MS mapping. , 2003, Analytical chemistry.

[12]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[13]  Richard D. Smith,et al.  Utility of accurate mass tags for proteome-wide protein identification. , 2000, Analytical chemistry.

[14]  F. Miller,et al.  Profiling the progression of cancer: Separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis , 2003, Proteomics.

[15]  Mukesh Verma,et al.  Proteomics for Cancer Biomarker Discovery , 2002 .

[16]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[17]  R. Kuick,et al.  A database of protein expression in lung cancer , 2001, Proteomics.

[18]  G. Wright,et al.  Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.

[19]  S Hanash,et al.  Proteomics in early detection of cancer. , 2001, Clinical chemistry.

[20]  T. K. Seow,et al.  Proteome analysis of a human heptocellular carcinoma cell line, HCC‐M: An update , 2001, Electrophoresis.

[21]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[22]  Min Zhan,et al.  A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.

[23]  Emanuel F. Petricoin,et al.  Clinical Applications of Proteomics: Proteomic Pattern Diagnostics , 2002, Journal of Mammary Gland Biology and Neoplasia.

[24]  S M Hanash,et al.  Biomedical applications of two‐dimensional electrophoresis using immobilized pH gradients: Current status , 2000, Electrophoresis.

[25]  N. Anderson,et al.  Multi‐component immunoaffinity subtraction chromatography: An innovative step towards a comprehensive survey of the human plasma proteome , 2003, Proteomics.

[26]  E. Sauter,et al.  Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer , 2002, British Journal of Cancer.

[27]  Joel G. Pounds,et al.  Proteomic Characterization of Nipple Aspirate Fluid: Identification of Potential Biomarkers of Breast Cancer , 2003, Breast Cancer Research and Treatment.

[28]  Thomas P Conrads,et al.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.

[29]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[30]  S. Gygi,et al.  Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Ronald J Moore,et al.  Global analysis of the Deinococcus radiodurans proteome by using accurate mass tags , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Vlahou,et al.  Proteomic approaches to biomarker discovery in prostate and bladder cancers , 2001, Proteomics.

[33]  Ronald J. Moore,et al.  Toward a Human Blood Serum Proteome , 2002, Molecular & Cellular Proteomics.

[34]  F. Miller,et al.  Protein profiles and identification of high performance liquid chromatography isolated proteins of cancer cell lines using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 1998, Rapid communications in mass spectrometry : RCM.

[35]  P. Dalbon,et al.  Differential diagnosis of prostate cancer and benign prostate hyperplasia using two‐dimensional electrophoresis , 2001, Electrophoresis.

[36]  E. Petricoin,et al.  The Vision for a New Diagnostic Paradigm , 2003 .

[37]  G. Mills,et al.  Lysophospholipids activate ovarian and breast cancer cells. , 1995, The Biochemical journal.